Piper Sandler analyst Matt O’Brien downgraded Teleflex (TFX) to Neutral from Overweight with a price target of $140, down from $255. The ...

Raymond James downgraded Teleflex (TFX) to Market Perform from Outperform without a price target The firm likes the company’s active portfolio ...

Principal Financial Group Inc. reduced its stake in Teleflex Incorporated (NYSE:TFX – Free Report) by 13.1% during the fourth ...

Teleflex Inc (TFX) reports a 2.8% revenue increase and a 15.1% rise in adjusted EPS, while announcing a strategic acquisition and share repurchase program to drive future growth.

After the split, Teleflex would focus on devices for bloodstream and heart procedures, along with medical imaging, while ...

Teleflex vascular access (24% of sales) is a no-moat business, in our view. While Teleflex leads the market for central venous catheters, or CVC, tubes that are connected to veins and used to deliver ...

Teleflex's business units, including urology and acute care will come under NewCo, with interventional and surgical under ...

The S&P 500 fell 1.6% on Thursday, Feb. 27, as Nvidia led semiconductor and AI stocks lower and investors digested President ...

Teleflex Inc. closed 44.33% below its 52-week high of $249.91, which the company reached on September 27th.

Good morning, ladies and gentlemen, and welcome to the Teleflex Fourth Quarter 2024 Earnings Conference Call. At this time all participants have been placed in a listen-only mode. At the end of the ...

Teleflex Incorporated (NYSE: TFX) has reported its financial results for the fourth quarter and full year 2024. In the fourth ...

Teleflex, whose shares sank nearly 20% Thursday, will acquire most of Biotronik’s vascular intervention assets. Teleflex also ...